METTL3 and neoplasm: Myeloid-specific ablation of Mettl3 increased tumor growth and metastasis and weakened the efficacy of anti-PD-1 therapy, in part by skewing macrophage polarization and altering inflammatory signaling, linking m6A to macrophage programming that shapes T-cell responses (90).